Clinical Trial

A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

Name: A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC — clinical trial record (NCT06913218)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

To explore safety and efficacy of neoantigen personalized mRNA vaccines AK154 monotherapy or in combination with AK104/AK112 and sequential mFOLFIRINOX regime in Resected PDAC

Trial Details

NCT Number	NCT06913218
Lead Sponsor	Akeso Collaborators: Fudan University
Conditions	Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma
Enrollment	60 participants
Start Date	2025-07-22
Primary Completion	2028-02-23 (estimated)
Study Completion	2028-11-06 (estimated)
Updated on ClinicalTrials.gov	2025-04-06